Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Flashback: Top five wildest moments from Elon Musk’s...
Less than half of DOGE-terminated contracts can be...
Jill Biden should have to answer for ‘cover...
DOGE staffing shakeup as Elon Musk hangs up...
State Dept says DOGE’s changes will be permanent...
President Trump teases ‘last day, but not really’...
Trump denounces court’s ‘political’ tariff decision, calls on...
I’m a physician and I’m worried that our...
Inside the late-night drama that led to Trump’s...
Alleged attempt to impersonate White House chief of...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

by admin November 19, 2024
November 19, 2024
Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.

  • The Human Research Ethics Committee (HREC) in Australia has approved the inclusion of five additional PD-L1 expressing solid tumors, beyond Non Small Cell Lung Cancer (NSCLC), for a Phase 1 therapeutic trial of RAD204.
  • 16 patients previously dosed in a Phase 1 diagnostic study demonstrated safety and biodistribution, validating the potential of 177Lu-RAD204 for the treatment of advanced PD-L1 expressing cancers.

The open-label Phase 1 trial, entitled “Phase 0/1 Study of the Safety and Tolerability of 177Lu- RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death- Ligand 1 in Patients with Metastatic Solid Tumours”, is a First-In-Human dose escalation trial of 177Lu- RAD2041, and is designed to evaluate the safety and preliminary clinical activity of this novel radiotherapeutic in eligible individuals with PD-L1 expressing advanced cancers.

The trial is currently ongoing and recruiting at four sites across New South Wales, South Australia and Western Australia, with the support of leading oncology care provider GenesisCare CRO.

RAD204 is a single-domain monoclonal antibody (sdAb) that targets PD-L1, a protein that helps control the immune system and is overexpressed in many solid cancers, making it an attractive therapeutic target in tumor types that include NSCLC, SCLC, TNBC, Cutaneous Melanoma, HNSCC, and Endometrial Cancer2. Previously published3 Phase I imaging data of 16 NSCLC patients with RAD204 have demonstrated that the diagnostic compound is safe and is associated with acceptable dosimetry. Tumor targeting with radioimmunotherapies such as 177Lu-RAD204 has the potential to address resistance mechanisms to current standard-of-care treatment options4.

“The implications of including additional PD-L1 expressing tumor types beyond NSCLC in this study is far-reaching,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “Patients with five additional PD-L1 expressing tumor types are now eligible for this basket trial, supporting the potential of 177Lu-RAD204 for a tumor-agnostic indication and as an effective radioimmunotherapy based on a pan-tumor predictive biomarker. With RAD204, we hope to provide an alternative strategy that can improve clinical outcomes for patients with PD-L1 positive advanced cancers, while potentially preserving their quality of life.”

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at radiopharmtheranostics.com.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
John Feneck: Why Gold is Down, 10+ Mining Stocks on My Radar Now
next post
Tim Scott says Biden regulators should quit it, give Trump a ‘fresh slate’

You may also like

1911 Gold Intersects up to 21.80 g/t Gold...

February 26, 2025

Gold Grades Continue to Impress at Northern Zone...

September 2, 2024

Silver Crown Royalties

August 1, 2024

AI Defines 18 New Gold Targets at Music...

February 18, 2025

Trump Administration Strikes 50/50 Minerals Deal with Ukraine

May 2, 2025

Suki Secures US$70 Million to Drive AI-Assisted Healthcare...

October 16, 2024

Coniagas Exploration Plan: Defining New Drill Targets and...

March 11, 2025

Hydrology Drilling to Support Scoping Study Commenced

January 17, 2025

Top 5 Canadian Mining Stocks This Week: Noble...

March 16, 2025

FREEGOLD ANNOUNCES CLOSING OF $42 MILLION BROKERED PRIVATE...

April 4, 2025

Recent Posts

  • Flashback: Top five wildest moments from Elon Musk’s DOGE tenure as it comes to an end
  • Less than half of DOGE-terminated contracts can be publicly tracked, only about a quarter of grants: watchdog
  • Jill Biden should have to answer for ‘cover up’ of former president’s decline, White House says
  • DOGE staffing shakeup as Elon Musk hangs up his hat, White House confirms
  • State Dept says DOGE’s changes will be permanent amid Musk’s departure

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (751)
    • Investing (2,211)
    • Politics (2,729)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.